BLRX Stock: Price, Forecast, Financials & AI Analysis

Loading...

Loading chart...

High

2.330

Open

2.330

VWAP

2.31

Vol

9.49K

Mkt Cap

9.79M

Low

2.295

Amount

21.94K

EV/EBITDA(TTM)

--

Total Shares

4.35M

EV

4.38M

EV/OCF(TTM)

--

P/S(TTM)

7.91

BioLine RX Ltd is an Israel-based clinical-stage biopharmaceutical company focused on oncology. The Company is commited into in-license novel compounds, develop them through clinical stages, and then partner with pharmaceutical companies for further clinical development andcommercialization. The Company is commited into two projects: Motixafortide (BL-8040), which is a cancer therapy platform , and AGI-134, an immunotherapy treatment.

Show More

Events Timeline

(ET)

2026-03-26

07:10:00

BioLineRx Initiates First-in-Human Study of GLIX1

2026-03-23 (ET)

2026-03-23

07:10:00

BioLineRx to Initiate GLIX1 Clinical Trial by End of Month

2025-11-24 (ET)

2025-11-24

07:04:33

BioLineRx Announces Q3 EPS of 0c, Unchanged from Last Year

2025-09-29 (ET)

2025-09-29

07:06:08

BioLineRx and Hemispherian AS Form Joint Venture for GLIX1 Development

2025-08-14 (ET)

2025-08-14

07:03:01

BioLineRx reports Q2 EPS 0c vs. 0c last year

2025-05-30 (ET)

2025-05-30

08:43:01

BioLineRx upgraded to Buy from Hold at JonesResearch

2025-05-30

07:05:01

BioLineRx announces new data from Phase 2 combination trial of motixafortide

2025-05-27 (ET)

2025-05-27

07:03:06

BioLineRx reports Q1 EPS 0c vs. 0c last year

News

PRnewswire

03-26PRnewswire

BioLineRx Initiates First-in-Human Trial of GLIX1 for GBM

moomoo

BIOLINERX LAUNCHES PHASE 1/2A CLINICAL TRIAL OF GLIX1 FOR GLIOBLASTOMA (GBM) TREATMENT

PRnewswire

03-23PRnewswire

BioLineRx Initiates GLIX1 Clinical Trial for Glioblastoma

Newsfilter

03-23Newsfilter

BioLineRx to Initiate GLIX1 Clinical Trial for Glioblastoma

seekingalpha

03-23seekingalpha

BioLineRx Reports FY EPS Beat Despite Revenue Plunge

moomoo

BIOLINE RX LTD SET TO LAUNCH PHASE 1/2A CLINICAL TRIAL OF GLIX1 FOR GLIOBLASTOMA TREATMENT BY MONTH'S END

1 Analyst Rating

Wall Street analysts forecast BLRX stock price to rise

1 Buy

0 Hold

0 Sell

Moderate Buy

Current: 0.000

Low

12.00

Averages

12.00

High

12.00

Current: 0.000

Low

12.00

Averages

12.00

High

12.00

Jones Trading

Justin Walsh

Strong Buy

to

Hold

Downgrades

n/a

AI Analysis

2025-04-02

Reason

Jones Trading

Justin Walsh

Price Target

n/a

AI Analysis

2025-04-02

Downgrades

Strong Buy

to

Hold

Reason

JonesResearch analyst Justin Walsh downgraded BioLineRx to Hold from Buy without a price target following the Q4 report. BioLineRx is on "sounder financial footing" following cessation of U.S. commercial operations with a cash runway that extends into the second half of 2026, the analyst tells investors in a research note. However, the firm sees the stock remaining range bound until the company's pipeline assets are in-licensed or motixafortide generates additional favorable data in pancreatic cancer and gene therapy indications.

Valuation Metrics

The current forward P/E ratio for BioLine RX Ltd (BLRX.O) is 90.38, compared to its 5-year average forward P/E of 3.82. For a more detailed relative valuation and DCF analysis to assess BioLine RX Ltd's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

dotted line Image

N/A

5Y Average PE

3.82

Current PE

90.38

Overvalued PE

28.41

Undervalued PE

-20.78

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

dotted line Image

N/A

5Y Average EV/EBITDA

-1.26

Current EV/EBITDA

-5.20

Overvalued EV/EBITDA

0.25

Undervalued EV/EBITDA

-2.77

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

dotted line Image

N/A

5Y Average PS

13.39

Current PS

4.87

Overvalued PS

56.41

Undervalued PS

-29.64

Financials

AI Analysis

Annual

Quarterly

Related Community Screener

high growth stocks trading under $5

Intellectia · 184 candidates

Price: <= $5.00Annual Eps Yoy Growth: >= 20.0%Annual Revenue Yoy Growth: >= 20.0%

Ticker

Name

Market Cap$

TDH Holdings Inc

10.74M

ReTo Eco-Solutions Inc

2.60M

Iovance Biotherapeutics Inc

1000.00M

Loop Industries Inc

61.87M

Evaxion A/S

26.61M

Onconetix Inc

1.65M

Intellectia · 2866 candidates

Pe Ttm: <= 10

Ticker

Name

Market Cap$

SL Green Realty Corp

3.35B

Avadel Pharmaceuticals PLC

2.11B

HubSpot Inc

15.84B

Arrowhead Pharmaceuticals Inc

9.42B

PDF Solutions Inc

1.42B

Trivago NV

197.86M

Whales Holding BLRX

Trading Trends

People Also Watch

Frequently Asked Questions

What is BioLine RX Ltd (BLRX) stock price today?

The current price of BLRX is 2.31 USD — it has increased 2.67

What is BioLine RX Ltd (BLRX)'s business?

BioLine RX Ltd is an Israel-based clinical-stage biopharmaceutical company focused on oncology. The Company is commited into in-license novel compounds, develop them through clinical stages, and then partner with pharmaceutical companies for further clinical development andcommercialization. The Company is commited into two projects: Motixafortide (BL-8040), which is a cancer therapy platform , and AGI-134, an immunotherapy treatment.

What is the price predicton of BLRX Stock?

Wall Street analysts forecast BLRX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BLRX is12.00 USD with a low forecast of 12.00 USD and a high forecast of 12.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is BioLine RX Ltd (BLRX)'s revenue for the last quarter?

BioLine RX Ltd revenue for the last quarter amounts to 427.00K USD, decreased -91.36

What is BioLine RX Ltd (BLRX)'s earnings per share (EPS) for the last quarter?

BioLine RX Ltd. EPS for the last quarter amounts to -0.00 USD, decreased

How many employees does BioLine RX Ltd (BLRX). have?

BioLine RX Ltd (BLRX) has 24 emplpoyees as of April 01 2026.

What is BioLine RX Ltd (BLRX) market cap?

Today BLRX has the market capitalization of 9.79M USD.